Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial.
Adding chemotherapy before standard treatment didn't improve survival for advanced nasopharyngeal cancer but did reduce quality-of-life side effects like difficulty swallowing.
Induction TPF followed by CCRT did not improve 3-year PFS vs adjuvant PF after CCRT in locally advanced NPC (79% vs 74.5%, P=0.454, n=266, 39-month follow-up); induction increased hematological toxicity but reduced nausea, dysphagia, and dry mouth. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- phase_III_rct
- Category
- sentinel
- Maturity
- Potentially Practice-Changing
- Journal
- Radiotherapy and Oncology
Why it surfaced
Phase III RCT providing first-level evidence for sequencing of chemotherapy in locally advanced NPC; definitive negative primary endpoint with important toxicity trade-off; NCT-registered multicenter design; sentinel-level clinical trial event.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.